Viewing Study NCT02826005



Ignite Creation Date: 2024-05-06 @ 8:47 AM
Last Modification Date: 2024-10-26 @ 12:05 PM
Study NCT ID: NCT02826005
Status: UNKNOWN
Last Update Posted: 2016-07-12
First Post: 2016-07-04

Brief Title: Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population
Sponsor: Ilex Medical
Organization: Ilex Medical

Study Overview

Official Title: Examination the Ability to Early Diagnose HCC
Status: UNKNOWN
Status Verified Date: 2016-07
Last Known Status: ENROLLING_BY_INVITATION
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Examination the ability to early diagnose HCC by combining three biomarkers technology developed by WAKO And their relevance to cirrhotic of patients with various backgrounds and the Israeli population

This blood test will serve as an additional diagnostic tool tools currently in use Ultrasound and AFP levels to cirrhotic patients with high risk to develop hepatocellular carcinoma

Another group that will be examined for all three biomarkers will be patients which already diagnosed with hepatocellular carcinoma and have normal AFP level in order to examine the correlation between the presence of tumor the number of them and the tumor size and the three biomarkers concentration in their blood
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None